Skip to main content

Rivaroxaban Stands up to Standard Anticoagulation for VTE Treatment


ATLANTA, Georgia — New data from a pooled analysis of theEINSTEIN-DVT and EINSTEIN-PE in the treatment of deep venous thrombosis (DVT) or pulmonary embolism suggests thatrivaroxaban (Xarelto, Bayer/ Janssen) is similarly effective in preventing recurrence of venous thromboembolism (VTE) asenoxaparin followed by a vitamin-K antagonist and may be associated with less bleeding.
In addition, subgroup analysis showed reassuring results in specific high-risk populations such as elderly, fragile patients, those with cancer, and those with large clots.
The data was presented at the American Society of Hematology (ASH) 2012 Annual Meeting by Dr Harry Buller (Academic Medical Center, Amsterdam, the Netherlands).
He noted that the EINSTEIN-DVT and EINSTEIN-PE trials had identical noninferiority designs comparing oral rivaroxaban (15 mg twice daily for three weeks then 20 mg once daily thereafter for up to 12 months) with enoxaparin for five to 10 days followed by an oral vitamin-K antagonist. In total, 8282 patients were enrolled into the two trials. The mean age was 57 in both treatment groups, and 50% of the patients were male.
Results of the pooled analysis showed a similar efficacy rate with the two treatments. The primary safety end point--major or nonmajor clinically relevant bleeding--was also similar in the two arms. But major bleeding alone appeared to be significantly reduced with rivaroxaban
Main Results From EINSTEIN Databases Combined
OutcomeRivaroxaban (%)Enoxaparin/vitamin-K antagonist (%)HR (95% CI)
Recurrence of thromboembolism2.12.30.89 (0.66–1.19)
Major or nonmajor clinically relevant bleeding9.410.00.93 (0.81–1.06)
Major bleeding1.01.70.54 (0.37–0.79)
Buller commented: "We have clear evidence of noninferiority with regard to recurrence of thromboembolism and a large reduction in major bleeding compared with the current standard of care. And this is with a much more convenient oral drug that does not need monitoring."
Focus on High-Risk Subgroups
Buller noted that while doctors seem to be welcoming the new oral anticoagulants for use in younger, more robust patients, there is the usual caution over use of a new drug in more fragile patients such as the elderly, those with cancer, and others at a high bleeding risk. Also, physicians are generally reluctant to use new agents in patients with a particularly large clot. "We wanted to look at these groups in this large database of the two EINSTEIN trials combined."
First of all, fragile patients--those who were elderly (over 75 years), had a body weight under 50 kg, or those with renal failure (creatinine clearance <50 mL/min)--were investigated, with around 790 such patients in each treatment arm. There was a trend in favor of rivaroxaban in effectiveness and a significant reduction in major bleeding in this group, Buller reported. He commented: "From these data, you would be wrong not to use rivaroxaban in fragile patients. It appears much safer than standard therapy."
EINSTEIN Databases Combined: Results in Fragile Patients
OutcomeRivaroxaban (%)Enoxaparin/vitamin-K antagonist (%)HR (95% CI)
Recurrence of thromboembolism2.73.80.68 (0.39–1.18),
Major bleeding1.34.50.27 (0.13–0.54)
The second group of interest included those with cancer, who made up about 200 patients in each treatment arm. Buller said "The numbers in this analysis are small and so need to be interpreted with caution, but again they look reassuring, with no evidence of an increase in bleeding with rivaroxaban."
EINSTEIN Databases Combined: Results in Cancer Patients
OutcomeRivaroxaban (%)Enoxaparin/vitamin K antagonist (%)HR (95% CI)
Recurrence of thromboembolism2.64.00.62 (0.22–1.8),
Major bleeding2.64.10.61 (0.21–1.77)
The last subgroup focused on were patients with a large clot. About this group, Buller commented: "Results show no indication that rivaroxaban isn't just as effective as low-molecular-weight heparin followed by a vitamin-K antagonist in patients with a large clot. I think we can use it with confidence in these patients."

Recurrence of Thromboembolism in Patients With Different Categories of Clot
Category of clotRivaroxaban (%)Enoxaparin/vitamin-K antagonist (%)p
Limited1.42.3NS
Intermediate2.42.6NS
Extensive2.32.1NS

Buller acts as a consultant and/or receives research funding from Bayer, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Pfizer, Sanofi, Roche, Isis, and Thrombogenics.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more